THERMO FISHER SCIENTIFIC INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.03 CAD | -1.17% |
|
-4.10% | -.--% |
| 05-31 | Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation | CI |
| 05-24 | Declaration of Voting Results by Thermo Fisher Scientific Inc | CI |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 35.67 and 30.59 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 217B | - | ||
| +12.99% | 190B | B- | ||
| +19.71% | 143B | B- | ||
| +30.60% | 111B | A- | ||
| +0.65% | 64.59B | A- | ||
| +15.23% | 52.36B | B+ | ||
| +2.06% | 48.45B | B+ | ||
| -5.49% | 38.03B | A | ||
| -0.22% | 35.6B | - | ||
| +20.56% | 30.31B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- TMO Stock
- TMO Stock
- Ratings Thermo Fisher Scientific Inc.